Geen internetverbinding — de opgeslagen versie van de pagina wordt getoond.

Exelixis Inc

USUSD
← Naar de screener

Exelixis Inc (LSE:0IJO) — Biotechnology: Biological Products (No Diagnostic Substances). Aantal beurzen waarop de aandelen van het bedrijf worden verhandeld: 3. Op deze pagina — koers en grafiek, dividenden, grootste aandeelhouders en historiek van het aantal aandelen.

Over het bedrijf

Website
exelixis.com
Beleggersrelaties
ir.exelixis.com/
Sector
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Hoofdkantoor
South San Francisco, United States
CEO
Michael M. Morrissey
Werknemers
1 077
Opgericht
1994
Uitstaande aandelen
247.78 mln. per 2026-07-27
Free float
213.6 mln.
Marktkapitalisatie
14.36 mld. USD
Insiders
1.85%
Institutionele beleggers
106.81%
Branche (SIC)
Biological Products, (No Diagnostic Substances)
ISIN
US30161Q1040
LEI
254900PJQB59O2O95R37
Uitkeringsratio
0%
FCF
1.17 mld. USD
Schuld
0 USD
netto kaspositie
Dividendreeks
—
Winst, FCF en uitbetaalde dividenden — voor de 12 maanden tot 03.07.2026 (het laatste rapport van het bedrijf).
Beschrijving

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Beurzen en tickers

BeursTickerValutaPrijsType
US USA StocksEXEL primairUSD59.02 +0.99%gewone aandelen
LSE London Stock Exchange0IJO IOBUSD59.69 +0.00%gewone aandelen
MI Borsa Italiana (Milan)1EXEL secundairEUR52.01 -0.27%gewone aandelen

Koers over 3 maanden

stijgingsdag dalingsdag ex-dividenddatum betaaldatumBeweeg over / tik op een dag — openings-, slot-, hoogste en laagste koers

Dividenden

Er zijn geen dividenduitkeringen gevonden (gecontroleerd op 10.10.2026). Het bedrijf keert waarschijnlijk geen dividend uit.

Nieuws deze week

Nog geen nieuws van de website van het bedrijf.

advertentie

Grootste aandeelhouders

HouderBelangAandelenRapportdatum
Blackrock Inc.11.73%29.08 mln.2026-06-30
Farallon Capital Managem…5.44%13.47 mln.2026-06-30
Renaissance Technologies…5.42%13.43 mln.2026-06-30
Vanguard Portfolio Manag…4.86%12.04 mln.2026-06-30
AQR Capital Management,…4.45%11.02 mln.2026-06-30
Vanguard Capital Managem…4.42%10.95 mln.2026-06-30
State Street Corporation4.02%9.97 mln.2026-06-30
Fuller & Thaler Asset Ma…3.6%8.93 mln.2026-06-30
iShares Trust-iShares Co…3.55%8.8 mln.2026-08-31
LSV Asset Management3.29%8.15 mln.2026-06-30
Geode Capital Management…3.09%7.65 mln.2026-06-30
VANGUARD INDEX FUNDS-Van…3.06%7.58 mln.2026-06-30
Capitol Series Trust-Ful…2.84%7.04 mln.2026-06-30
VANGUARD INDEX FUNDS-Van…2.21%5.47 mln.2026-06-30
MORRISSEY MICHAEL M (Chi…≈1.37%3.38 mln.2026-05-18
VANGUARD INDEX FUNDS-Van…1.27%3.16 mln.2026-06-30
VANGUARD INDEX FUNDS-Van…1.16%2.88 mln.2026-06-30
Invesco Exchange-Traded…1.12%2.78 mln.2026-08-31
SPDR SERIES TRUST-State…0.8%1.99 mln.2026-08-31
SPDR S&P MIDCAP 400 ETF…0.74%1.84 mln.2026-08-31
iShares Trust-iShares Bi…0.74%1.82 mln.2026-08-31
PAPADOPOULOS STELIOS B (…≈0.48%1.2 mln.2026-05-27
SENNER CHRISTOPHER J. (C…≈0.39%955 0402026-05-18
HESSEKIEL JEFFREY J (Gen…≈0.28%694 3952025-05-15
AFTAB DANA T. (Officer)≈0.24%600 5762026-05-26
PETERSON AMY C (Officer)≈0.19%465 3932025-05-16
HALEY PATRICK JOSEPH (Of…≈0.14%357 6382026-05-20
WYSZOMIERSKI JACK L (Dir…≈0.11%284 3842026-06-01
POSTE GEORGE H (Director…≈0.05%127 1992026-05-27
JOHNSON DAVID EDWARD (Di…——2025-11-25